Grade II Meningioma
Back to Diseases List
Associated Genetic Biomarkers
NCI Definition: An atypical meningioma which may recur in approximately 29-40% of the cases. This category includes the atypical meningioma, chordoid meningioma, and clear cell meningioma. 
Grade II meningiomas most frequently harbor alterations in NF2, CDKN2A, SMO, ROS1, and PTEN .
NF2fs, NF2 Mutation, NF2 Nonsense, CDKN2A Loss, and SMO Mutation are the most common alterations in grade II meningioma .
There are 4 clinical trials for grade II meningioma, of which 3 are open and 1 is completed or closed. Of the trials that contain grade II meningioma as an inclusion criterion, 1 is phase 1/phase 2 (1 open) and 3 are phase 2 (2 open).
SSTR2 is the most frequent gene inclusion criterion for grade II meningioma clinical trials .
Novottf-100a device, bevacizumab, and ipilimumab are the most common interventions in grade II meningioma clinical trials.
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.